

Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: BM1/21 - Bone Markers

Deadline: 16.04.2021

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability												
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
(431) Parathyroid hormone (PTH)					28							27	25	93%
Samples and groups	[pmol/L]													
Sample A		7,00	1,5	21	28							27	25	93%
(1) Immunochemical meth.; (60) Roche		6,58	0,67	10	16	0	CVPG	6,57	0,20	23%	5,05	8,09	16	
(1) Immunochemical meth.; (179) Siemens		7,65	0,67	8,8	6	0	CVPG	7,44	0,36	23%	5,72	9,16	6	
Other					6	1							5	
								3x 1/1, 2x 1/12, 1x 1/29						
Sample B		19,9	4,0	20	28							27	25	93%
(1) Immunochemical meth.; (60) Roche		19,0	1,7	9,1	16	1	CVPG	19,6	0,54	23%	15	24,2	16	
(1) Immunochemical meth.; (179) Siemens		22,0	1,6	7,4	6	0	CVPG	21,9	0,97	23%	16,8	27	6	
Other					6	0							5	
								3x 1/1, 2x 1/12, 1x 1/29						
(432) Collagen telopeptide CTx-beta					20							19	16	84%
Samples and groups	[ng/L]													
Sample A		294	39	13	20							19	16	84%
(1) Immunochemical meth.; (60) Roche		297	36	12	19	0	CVPG	304	6,2	17%	252	356	19	
Other					1	0							0	
								1x 1/183						
Sample B		764	110	14	20							19	16	84%
(1) Immunochemical meth.; (60) Roche		773	100	13	19	0	CVPG	790	18	17%	655	925	19	
Other					1	0							0	
								1x 1/183						
(433) P1NP					14							14	14	100%
Samples and groups	[µg/L]													
Sample A		28,4	1,5	5,4	14							14	14	100%
(1) Immunochemical meth.; (60) Roche		28,4	1,5	5,4	14	0	CVPG	28,9	0,43	20%	23,1	34,7	14	
Sample B		167	6,0	3,6	14							14	14	100%
(1) Immunochemical meth.; (60) Roche		167	6,0	3,6	14	0	CVPG	172	3,0	20%	137	207	14	
(434) Osteocalcin					19							17	14	82%
Samples and groups	[µg/L]													
Sample A		18,7	0,92	4,9	19							17	14	82%
(1) Immunochemical meth.; (60) Roche		18,8	0,82	4,4	17	0	CVPG	19	0,28	13%	16,5	21,5	17	
Other					2	0							0	
								1x 1/24, 1x 164						
Sample B		93,8	7,4	7,9	19							17	15	88%
(1) Immunochemical meth.; (60) Roche		94,0	5,8	6,2	17	0	CVPG	95,4	1,5	13%	82,9	108	17	
Other					2	0							0	
								1x 1/24, 1x 164						
(435) 25-hydroxyvitamin D					28							26	26	100%
Samples and groups	[nmol/L]													
Sample A		86,1	20	23	28							26	26	100%
(1) Immunochemical meth.; (256) Roche (2)		92,1	13	14	20	0	CVPG	92,9	3,2	33%	62,2	124	20	
Other					8	0							6	
								4x 1/1, 1x 1/12, 1x 1/149, 1x 1/179, 1x 2/998						
Sample B		171	33	19	28							26	26	100%
(1) Immunochemical meth.; (256) Roche (2)		180	23	13	20	0	CVPG	180	6,4	33%	120	240	20	
Other					8	0							6	
								4x 1/1, 1x 1/12, 1x 1/149, 1x 1/179, 1x 2/998						

st_kn_p

End of report

Printed: 23.04.2021